Silence Therapeutics Statistics
Share Statistics
Silence Therapeutics has 47.21M shares outstanding. The number of shares has increased by 1.53% in one year.
| Shares Outstanding | 47.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.89% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 37.55M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 353.32K, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 353.32K |
| Short % of Shares Out | 0.75% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 2.36 |
Valuation Ratios
The PE ratio is -11.71 and the forward PE ratio is null.
| PE Ratio | -11.71 |
| Forward PE | null |
| PS Ratio | 19.96 |
| Forward PS | 15.8 |
| PB Ratio | 29.71 |
| P/FCF Ratio | -12.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Silence Therapeutics has an Enterprise Value (EV) of 452.85M.
| EV / Earnings | -10.47 |
| EV / Sales | 17.85 |
| EV / EBITDA | -9.1 |
| EV / EBIT | -9.13 |
| EV / FCF | -11.5 |
Financial Position
The company has a current ratio of 4.56, with a Debt / Equity ratio of 0.
| Current Ratio | 4.56 |
| Quick Ratio | 5.61 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -1458.94 |
Financial Efficiency
Return on equity (ROE) is -2.54% and return on capital (ROIC) is -246.28%.
| Return on Equity (ROE) | -2.54% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -246.28% |
| Revenue Per Employee | 232.80K |
| Profits Per Employee | -396.94K |
| Employee Count | 109 |
| Asset Turnover | 0.27 |
| Inventory Turnover | -0.55 |
Taxes
| Income Tax | -7.04M |
| Effective Tax Rate | 0.14 |
Stock Price Statistics
The stock price has increased by -68.46% in the last 52 weeks. The beta is 1.29, so Silence Therapeutics's price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -68.46% |
| 50-Day Moving Average | 9.44 |
| 200-Day Moving Average | 17.15 |
| Relative Strength Index (RSI) | 27.43 |
| Average Volume (20 Days) | 511.16K |
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 25.38M and earned -43.27M in profits. Earnings per share was -1.17.
| Revenue | 25.38M |
| Gross Profit | 15.06M |
| Operating Income | -49.60M |
| Net Income | -43.27M |
| EBITDA | -49.78M |
| EBIT | -49.60M |
| Earnings Per Share (EPS) | -1.17 |
Balance Sheet
The company has 54.03M in cash and 272.00K in debt, giving a net cash position of 53.76M.
| Cash & Cash Equivalents | 54.03M |
| Total Debt | 272.00K |
| Net Cash | 53.76M |
| Retained Earnings | -304.61M |
| Total Assets | 169.38M |
| Working Capital | 140.60M |
Cash Flow
In the last 12 months, operating cash flow was -39.35M and capital expenditures -45.00K, giving a free cash flow of -39.40M.
| Operating Cash Flow | -39.35M |
| Capital Expenditures | -45.00K |
| Free Cash Flow | -39.40M |
| FCF Per Share | -1.06 |
Margins
Gross margin is 59.34%, with operating and profit margins of -195.48% and -170.51%.
| Gross Margin | 59.34% |
| Operating Margin | -195.48% |
| Pretax Margin | -198.27% |
| Profit Margin | -170.51% |
| EBITDA Margin | -196.17% |
| EBIT Margin | -195.48% |
| FCF Margin | -155.25% |
Dividends & Yields
SLN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -20.78% |
| FCF Yield | -14.82% |
Analyst Forecast
The average price target for SLN is $61, which is 983.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $61 |
| Price Target Difference | 983.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -0.1 |
| Piotroski F-Score | 3 |